Programmed cell death-ligand 1 (PD-L1) Pemphumab and Navumab have been shown to be effective in patients with metastatic colorectal cancer with defective mismatch repair and high microsatellite instability [11]. This evidence concerns the gene CD274 and metastatic colorectal cancer.